- Home
- SRZN vs EIC Comparison
SRZN vs EIC Comparison
Compare SRZN & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRZN | EIC |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.6M | 228.8M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SRZN | EIC |
|---|---|---|
| Price | $17.43 | $9.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $38.00 | $12.63 |
| AVG Volume (30 Days) | ★ 172.1K | 87.7K |
| Earning Date | 05-08-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 13.25% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,477,000.00 | N/A |
| Revenue This Year | $75.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.39 | $9.17 |
| 52 Week High | $35.00 | $13.55 |
Technical Indicators
Market Signals| Indicator | SRZN | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 23.83 | 28.35 |
| Support Level | N/A | $9.33 |
| Resistance Level | $23.55 | $10.14 |
| Average True Range (ATR) | 1.29 | 0.11 |
| MACD | -0.42 | -0.04 |
| Stochastic Oscillator | 4.15 | 5.74 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.